These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38500407)

  • 61. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.
    Laucella SA; Mazliah DP; Bertocchi G; Alvarez MG; Cooley G; Viotti R; Albareda MC; Lococo B; Postan M; Armenti A; Tarleton RL
    Clin Infect Dis; 2009 Dec; 49(11):1675-84. PubMed ID: 19877967
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Risk factors and select cardiac characteristics in dogs naturally infected with Trypanosoma cruzi presenting to a teaching hospital in Texas.
    Meyers AC; Hamer SA; Matthews D; Gordon SG; Saunders AB
    J Vet Intern Med; 2019 Jul; 33(4):1695-1706. PubMed ID: 31119786
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
    Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
    Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of essential oil of Syzygium aromaticum alone and in combination with benznidazole on murine oral infection with Trypanosoma cruzi IV.
    Zanusso Junior G; Massago M; Kian D; Toledo MJO
    Exp Parasitol; 2018 Feb; 185():92-97. PubMed ID: 29305891
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.
    Bustamante JM; Craft JM; Crowe BD; Ketchie SA; Tarleton RL
    J Infect Dis; 2014 Jan; 209(1):150-62. PubMed ID: 23945371
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Trypanosoma cruzi: alteration in the lymphoid compartments following interruption of infection by early acute benznidazole therapy in mice.
    Olivieri BP; de Souza AP; Cotta-de-Almeida V; de Castro SL; Araújo-Jorge T
    Exp Parasitol; 2006 Nov; 114(3):228-34. PubMed ID: 16620811
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
    Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
    Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease.
    Araújo MS; Martins-Filho OA; Pereira ME; Brener Z
    J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
    Cencig S; Coltel N; Truyens C; Carlier Y
    Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease.
    Santos FM; Lima WG; Gravel AS; Martins TA; Talvani A; Torres RM; Bahia MT
    J Antimicrob Chemother; 2012 Aug; 67(8):1987-95. PubMed ID: 22570424
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.
    Novaes RD; Santos EC; Cupertino MC; Bastos DS; Oliveira JM; Carvalho TV; Neves MM; Oliveira LL; Talvani A
    Parasitol Res; 2015 Aug; 114(8):2873-81. PubMed ID: 25912691
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.
    Albareda MC; Laucella SA
    Mem Inst Oswaldo Cruz; 2015 May; 110(3):414-21. PubMed ID: 25993507
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.